Literature DB >> 30515045

Sulfasalazine-Induced Interstitial Fibrosis.

Bugra Kerget1, Omer Araz2, Elif Yilmazel Ucar2, Ozkan Aydin3, Metin Akgun2, Leyla Saglam2.   

Abstract

Sulfasalazine has been used in the treatment of inflammatory bowel disease for over 60 years. Although the drug is frequently associated with gastrointestinal adverse effects, pulmonary adverse effects are very rare. Herein, we report a case of interstitial fibrosis resulting from 4-month sulfasalazine therapy for ulcerative colitis in a patient under long-term follow-up in our clinic due to chronic obstructive pulmonary disease.

Entities:  

Keywords:  Pulmonary fibrosis; sulfasalazine; ulcerative colitis

Year:  2018        PMID: 30515045      PMCID: PMC6263240          DOI: 10.5152/eurasianjmed.2018.17302

Source DB:  PubMed          Journal:  Eurasian J Med        ISSN: 1308-8734


  4 in total

Review 1.  [Pulmonary manifestations of inflammatory bowel disease].

Authors:  M C Vennera; C Picado
Journal:  Arch Bronconeumol       Date:  2005-02       Impact factor: 4.872

Review 2.  Current treatment of ulcerative colitis.

Authors:  Johannes Meier; Andreas Sturm
Journal:  World J Gastroenterol       Date:  2011-07-21       Impact factor: 5.742

3.  Sulfasalazine-induced pulmonary disease.

Authors:  M A Hamadeh; J Atkinson; L J Smith
Journal:  Chest       Date:  1992-04       Impact factor: 9.410

4.  Bronchiolitis obliterans organizing pneumonia associated with sulfasalazine in a patient with rheumatoid arthritis.

Authors:  Bahar Ulubaş; Günşah Sahin; Caner Ozer; Ozlem Aydin; Eylem Ozgür; Demir Apaydin
Journal:  Clin Rheumatol       Date:  2004-02-24       Impact factor: 2.980

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.